Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.485
-0.005 (-0.20%)
Aug 27, 2026, 2:49 PM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $452.46 million as of August 27, 2026. Its market cap has increased by 173.12% in one year.
Market Cap
452.46M
Enterprise Value
293.44M
1-Year Change
173.12%
Ranking
Category
Stock Price
$2.49
ChartMarket Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $452.46M, an increase of 350.40%. That is a compound annual growth rate of 30.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 27, 2026 | 452.46M | 61.36% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Prothena Corporation | 483.59M |
| Capricor Therapeutics | 481.97M |
| Puma Biotechnology | 481.10M |
| Ocugen | 474.75M |
| Compass Therapeutics | 455.62M |
| Benitec Biopharma | 447.29M |
| Arcturus Therapeutics Holdings | 438.85M |
| Vogenx | 438.82M |